Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Dare Bioscience (DARE) Gross Margin (2023 - 2025)

Dare Bioscience's Gross Margin history spans 3 years, with the latest figure at 71.1% for Q4 2025.

  • For Q4 2025, Gross Margin fell 1684.0% year-over-year to 71.1%; the TTM value through Dec 2025 reached 71.29%, down 2871.0%, while the annual FY2025 figure was 71.29%, 2871.0% down from the prior year.
  • Gross Margin reached 71.1% in Q4 2025 per DARE's latest filing, down from 100.0% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q3 2023 to a low of 17.5% in Q1 2024.
  • Average Gross Margin over 3 years is 86.28%, with a median of 100.0% recorded in 2023.
  • The largest YoY upside for Gross Margin was 8250bps in 2025 against a maximum downside of -1684bps in 2025.
  • A 3-year view of Gross Margin shows it stood at 100.0% in 2023, then decreased by -12bps to 87.94% in 2024, then decreased by -19bps to 71.1% in 2025.
  • Per Business Quant, the three most recent readings for DARE's Gross Margin are 71.1% (Q4 2025), 100.0% (Q3 2025), and 100.0% (Q2 2025).